Recombinant Envafolimab Biosimilar 抗体
The Humanized 单克隆 anti-Envafolimab Biosimilar antibody is suitable to detect Envafolimab Biosimilar in samples from 人. It has been validated for FACS 和 in vivo.
产品编号 ABIN7795134
发货至:
中国
Contact our Customer Service for availability and price in your country.
Contact Info
Our Local Distributor
中国
北京 101111
北京 101111
No. 88 KeChuang 6th Street
Beijing Economic Technological Development Area
Room 801-803
Quick Overview for Recombinant Envafolimab Biosimilar 抗体 (ABIN7795134)
抗原
Envafolimab Biosimilar
抗体类型
Recombinant Antibody
适用
人
宿主
Humanized
克隆类型
单克隆
应用范围
Flow Cytometry (FACS), In vivo Studies (in vivo)
质量等级
Research Grade
-
-
Expression System
- Mammalian cells
-
原理
- Envafolimab Biosimilar, PD-L1 Monoclonal Antibody
-
产品特性
- What is envafolimab biosimilar research grade? Envafolimab is a humanized nanobody (VHH-hIgG1 Fc fusion protein) directed against the human protein ligand PD-L1, with potential immune checkpoint inhibitory and antineoplastic activities. Envafolimab biosimilar uses the same protein sequences as the therapeutic antibody envafolimab. PD-L1 (B7-H1 or CD274, programmed cell death ligand 1) and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed death 1). PD-L1 is an immune checkpoint molecule expressed on both tumor cells and certain immune cells. The binding of PD-L1 to its receptors PD-1 or B7.1 on activated T cells causes an inhibitory signal to suppress their production in the lymph nodes, thereby preventing immune responses to events such as pregnancy or autoimmune disease. This pathway is also utilized by cancer cells to evade the immune system through evasion of anti-tumor T-cell response. Furthermore, over-expression of PD-L1 and PD-1 has been linked to increased tumor aggressiveness and poorer prognosis. Envafolimab binds directly and selectively to PD-L1 and blocks interaction with both PD-1 and B7.1 receptors, thus reinvigorates and enhances the body's adaptive anti-cancer activity. Disrupting the PD-L1/B7.1 interaction may also enhance T-cell priming, which could result in increased duration of response and survival.
-
纯化方法
- Protein A or G affinity column
-
纯度
- >95 % by reducing SDS-PAGE
-
内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method
-
免疫原
- Human PD-L1
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
限制
- 仅限研究用
-
-
-
状态
- Liquid
-
浓度
- > 3 mg/mL
-
储存条件
- 4 °C,-20 °C
-
储存方法
- Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.
-
-
- Envafolimab Biosimilar
-
物质类
- Biosimilar
抗原
-
You are here:
